Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says
() -- Alnylam Pharmaceuticals' (ALNY) Q2 financial results will be important in determining where 2026 revenue will fall within the guidance range and whether management would further refine that guidance, BofA Securities said in a note Tuesday. The investment firm said it remains bullish on the large commercial opport